Firebrick Pharma Limited (ASX:FRE)

Market Cap	8.33M -51.8%
Revenue (ttm)	135.62K -73.7%
Net Income	-3.06M
EPS	-0.01
Shares Out	287.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	620,077
Open	0.0290
Previous Close	0.0280
Day's Range	0.0290 - 0.0290
52-Week Range	0.0240 - 0.0740
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Firebrick Pharma

Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: FRE

Financial Performance

In fiscal year 2026, Firebrick Pharma's revenue was 135,615, a decrease of -73.69% compared to the previous year's 515,507. Losses were -3.06 million, 16.3% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error